text:  you know, the challenge now is also trying to get this DNA or this system into the different cells. And then also it's a long process going through the FDA and all of that stuff. That's actually one of the reasons we went with the path that I just described about the antibody generation, because it's a simpler, easier path. It's not a therapeutic. We're just helping people make antibodies or other things that are similar to antibodies faster. So it was kind of a